Literature DB >> 10348217

A case of aldosterone-producing adenoma with severe postoperative hyperkalemia.

R Taniguchi1, H Koshiyama, M Yamauchi, S Tanaka, D Inoue, Y Sato, A Sugawa, Y Muramatsu, H Sasano.   

Abstract

It is known that some patients with primary aldosteronism show postoperative hyperkalemia, which is due to inability of the adrenal gland to secrete sufficient amounts of aldosterone. However, hyperkalemia is generally neither severe nor prolonged, in which replacement therapy with mineralocorticoid is seldom necessary. We report a case of a 46-year-old woman with an aldosterone-producing adenoma associated with severe postoperative hyperkalemia. After unilateral adrenalectomy, the patient showed episodes of severe hyperkalemia for four months, which required not only cation-exchange resin, but also mineralocorticoid replacement. Plasma aldosterone concentration (PAC) was low, although PAC was increased after rapid ACTH test. Histological examination indicated the presence of adrenocortical tumor and paradoxical hyperplasia of zona glomerulosa in the adjacent adrenal. Immunohistochemistry demonstrated that the enzymes involved in aldosterone synthesis, such as cholesterol side chain cleavage (P-450scc), 3beta-hydroxysteroid dehydrogenase (3beta-HSD), and 21-hydroxylase (P-450c21), or the enzyme involved in glucocorticoid synthesis, 11beta-hydroxylase (P-450c11beta), were expressed in the tumor, but they were completely absent in zona glomerulosa of the adjacent adrenal. These findings were consistent with the patterns of primary aldosteronism. Serum potassium level was gradually decreased with concomitant increase in PAC. These results suggest that severe postoperative hyperkalemia of the present case was attributable to severe suppression of aldosterone synthesis in the adjacent and contralateral adrenal, which resulted in slow recovery of aldosterone secretion. It is plausible that aldosterone synthesis of adjacent and contralateral adrenal glands is severely impaired in some cases with primary aldosteronism, as glucocorticoid synthesis in Cushing syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10348217     DOI: 10.1620/tjem.186.215

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  6 in total

Review 1.  Adrenal incidentalomas: surgical treatment in 28 patients and update of the literature.

Authors:  A B Porcaro; G Novella; V Ficarra; P Curti; S Z Antoniolli; H S Suangwoua; G Malossini
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 2.  [Persistent and serious hyperkalemia after surgery of primary aldosteronism: A case report].

Authors:  W Wang; L Cai; Y Gao; X H Guo; J Q Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

Review 3.  A case of normoreninemic aldosterone-producing adenoma associated with chronic renal failure: case report and literature review.

Authors:  Hiroyuki Koshiyama; Takeshi Fujisawa; Naomitsu Kuwamura; Yoshio Nakamura; Hiroshi Kanamori; Emi Oida; Akira Hara; Takashi Suzuki; Hironobu Sasano
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

4.  A case report of hyponatremia after surgery for Conn's adenoma.

Authors:  Giulia Furlanis; Stella Bernardi; Monica Cavressi; Lorenzo Zandonà; Renzo Carretta; Bruno Fabris; Moreno Bardelli
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017 Oct-Dec       Impact factor: 1.636

5.  Unmasked renal impairment and prolonged hyperkalemia after unilateral adrenalectomy for primary aldosteronism coexisting with primary hyperparathyroidism: report of a case.

Authors:  Yatsuka Hibi; Nobuki Hayakawa; Midori Hasegawa; Kimio Ogawa; Yoshimi Shimizu; Masahiro Shibata; Chikara Kagawa; Yutaka Mizuno; Yukio Yuzawa; Mitsuyasu Itoh; Katsumi Iwase
Journal:  Surg Today       Date:  2013-12-17       Impact factor: 2.549

6.  Severe hyperkalemia following adrenalectomy for aldosteronoma: prediction, pathogenesis and approach to clinical management- a case series.

Authors:  A Tahir; K McLaughlin; G Kline
Journal:  BMC Endocr Disord       Date:  2016-07-27       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.